Antiviral drug discovery and development: Where chemistry meets with biomedicine

被引：153
作者：
De Clercq, E [1 ]
机构：
[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
来源：
ANTIVIRAL RESEARCH | 2005年 / 67卷 / 02期
关键词：
antivirals; HIV (AIDS); HBV (hepatitis B); HSVC (herpes simplex); VZV (herpes zoster); DNA viruses;
D O I：
10.1016/j.antiviral.2005.05.001
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The successful development of antiviral drugs is highly dependent on a close interaction and collaboration between the chemist and the biologist (biomedic). This is illustrated by a number of representative examples: S-adenosylhomocysteine (SAH) hydrolase inhibitors which display broad-spectrum antiviral activity, bromovinyldeoxyuridine (BVDU) and derivatives thereof, that are highly selective inhibitors of varicella-zoster virus (VZV), (dideoxy)nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) which are now widely used in the treatment of HIV infections (AIDS), the bicyclams (i.e. AMD3100) which were originally discovered as anti-HIV agents, then found to be potent CXCR4 antagonists and now being pursued for a number of indications such as stem cell mobilization, and the acyclic nucleoside phosphonates which have heralded a new strategy for the treatment of various DNA virus (herpes-, adeno-, pox-, papillomavirus) infections (cidofovir), hepatitis B (adefovir) and AIDS (tenofovir). (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码：56 / 75
页数：20
相关论文
共 45 条
[1]   Susceptibilities of several clinical Varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides [J].
Andrei, G ;
Sienaert, R ;
McGuigan, C ;
De Clercq, E ;
Balzarini, J ;
Snoeck, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :1081-1086
[2]  
ANDREI G, 2005, 18 INT C ANT RES BAR, V65, P38
[3]   PRECLINICAL EVALUATION OF MKC-442, A HIGHLY POTENT AND SPECIFIC INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN-VITRO [J].
BABA, M ;
SHIGETA, S ;
YUASA, S ;
TAKASHIMA, H ;
SEKIYA, K ;
UBASAWA, M ;
TANAKA, H ;
MIYASAKA, T ;
WALKER, RT ;
DECLERCQ, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :688-692
[4]   BOTH 2',3'-DIDEOXYTHYMIDINE AND ITS 2',3'-UNSATURATED DERIVATIVE (2',3'-DI-DEOXYTHYMIDINENE) ARE POTENT AND SELECTIVE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS-REPLICATION INVITRO [J].
BABA, M ;
PAUWELS, R ;
HERDEWIJN, P ;
DECLERCQ, E ;
DESMYTER, J ;
VANDEPUTTE, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 142 (01) :128-134
[5]   HIGHLY SPECIFIC-INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 BY A NOVEL 6-SUBSTITUTED ACYCLOURIDINE DERIVATIVE [J].
BABA, M ;
TANAKA, H ;
DECLERCQ, E ;
PAUWELS, R ;
BALZARINI, J ;
SCHOLS, D ;
NAKASHIMA, H ;
PERNO, CF ;
WALKER, RT ;
MIYASAKA, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 165 (03) :1375-1381
[6]   DIFFERENTIAL ANTIHERPESVIRUS AND ANTIRETROVIRUS EFFECTS OF THE (S) AND (R) ENANTIOMERS OF ACYCLIC NUCLEOSIDE PHOSPHONATES - POTENT AND SELECTIVE INVITRO AND INVIVO ANTIRETROVIRUS ACTIVITIES OF (R)-9-(2-PHOSPHONOMETHOXYPROPYL)-2,6-DIAMINOPURINE [J].
BALZARINI, J ;
HOLY, A ;
JINDRICH, J ;
NAESENS, L ;
SNOECK, R ;
SCHOLS, D ;
DECLERCQ, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (02) :332-338
[7]   POTENT AND SELECTIVE ANTI-HTLV-III/LAV ACTIVITY OF 2',3'-DIDEOXYCYTIDINENE, THE 2',3'-UNSATURATED DERIVATIVE OF 2',3'-DIDEOXYCYTIDINE [J].
BALZARINI, J ;
PAUWELS, R ;
HERDEWIJN, P ;
DECLERCQ, E ;
COONEY, DA ;
KANG, GJ ;
DALAL, M ;
JOHNS, DG ;
BRODER, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1986, 140 (02) :735-742
[8]  
BALZARINI J, 1988, MOL PHARMACOL, V33, P243
[9]   3-deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice [J].
Bray, M ;
Raymond, JL ;
Geisbert, T ;
Baker, RO .
ANTIVIRAL RESEARCH, 2002, 55 (01) :151-159
[10]   Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor [J].
Bray, M ;
Driscoll, J ;
Huggins, JW .
ANTIVIRAL RESEARCH, 2000, 45 (02) :135-147
12345